Clinical Trials

246 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT05590377 2026-01-30

iinnovate-3

Phase 1/2 Terminated

15 enrolled 12 charts

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence

NCT04824794 2025-12-22

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Phase 1/2 Terminated

130 enrolled

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Not yet recruiting

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07090954 2025-07-29

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

32 enrolled

Multiple Myeloma

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

19 enrolled

Multiple Myeloma, Recurrence

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

LymphoidOther hematologic neoplasmPlasma cell

128 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1/2 Active not recruiting

424 enrolled

Multiple Myeloma, Recurrence

NCT02488759 2023-11-13

CheckMate358

Other hematologic neoplasm

578 enrolled 19 charts

Various Advanced Cancer

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Hematologic Neoplasms

NCT03481556 2022-12-19

ANCHOR

Phase 1/2 Terminated

56 enrolled 22 charts

Multiple Myeloma

NCT03098550 2021-07-23

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

BreastGastrointestinalThoracic

105 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT03023423 2019-11-20

DARZALEX